Numerous studies in 2015 focused on therapeutic immune modulation and immunosuppression. Trials of budenoside in patients with IgA nephropathy who are unresponsive to supportive therapy, and of low-dose IL-2 to enforce regulatory T-cell-mediated immunosuppression in autoimmune disease all produced promising results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vecchio, M. et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst. Rev. 8, CD003965 (2015).
Rauen, T. et al. Corticosteroid monotherapy versus combined immunosuppression in IgA nephropathy. New Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1415463 (2015).
Kiryluk, K. & Novak, J. The genetics and immunobiology of IgA nephropathy. J. Clin. Invest. 124, 2325–2332 (2014).
Fellstrom, B. C. et al. The NEFIGAN Trial: NEFECON, a novel targeted release formulation of budesonide, reduces proteinuria and stabilizes eGFR in IgA nephropathy patients at risk of ESRD. J. Am. Soc. Nephrol. Abstr. 26, HI-OR04 (2015).
Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).
von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-207776 (2015).
Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791–792 (2015).
Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013).
Takao, K. & Miyakawa, T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 112, 1167–1172 (2015).
Kurts, C., Panzer, U., Anders, H. J. & Rees, A. J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738–753 (2013).
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (grant numbers AN372/11-2, AN372/12-2, AN372/14-3, AN372/15-1, AN372/16-1, AN372/17-1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H-J.A. has received consultancy fees from GlaxoSmithKline, Roche, and Bayer.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Anders, HJ. Updates on immunosuppression in kidney disease. Nat Rev Nephrol 12, 65–66 (2016). https://doi.org/10.1038/nrneph.2015.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.202
